Literature DB >> 19234494

Mild increase in coronary sinus pressure with coronary sinus reducer stent for treatment of refractory angina.

Yoav Paz1, Amihay Shinfeld.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19234494     DOI： 10.1038/ncpcardio1475

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN： 1743-4297


× No keyword cloud information.
  5 in total

1.  Experiences with the Beck operation for coronary artery disease.

Authors:  M W SELMAN
Journal:  Dis Chest       Date:  1955-07

2.  Surgical Treatment of Angina Pectoris : Experiences with Ligation of the Great Cardiac Vein and Pericoronary Neurectomy.

Authors:  M Fauteux
Journal:  Ann Surg       Date:  1946-12       Impact factor: 12.969

3.  Coronary venous pressure elevation 'risks and benefit'.

Authors:  Werner Mohl; Dejan Milasinovic; Günter Steurer
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

4.  Is activation of coronary venous cells the key to cardiac regeneration?

Authors:  Werner Mohl; Stefan Mina; Dejan Milasinovic; Hirofumi Kasahara; Sheng Wei; Gerald Maurer
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-09

5.  Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study.

Authors:  Shmuel Banai; Shmuel Ben Muvhar; Keyur H Parikh; Aharon Medina; Horst Sievert; Ashok Seth; Jonathan Tsehori; Yoav Paz; Ami Sheinfeld; Gad Keren
Journal:  J Am Coll Cardiol       Date:  2007-05-01       Impact factor: 24.094
  5 in total
  2 in total

1.  Coronary venous pressure elevation 'risks and benefit'.

Authors:  Werner Mohl; Dejan Milasinovic; Günter Steurer
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

2.  A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial.

Authors:  E Marc Jolicœur; Shmuel Banai; Timothy D Henry; Marc Schwartz; Serge Doucet; Christopher J White; Elazer Edelman; Stefan Verheye
Journal:  Trials       Date:  2013-02-15       Impact factor: 2.279
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.